Gerard R Dawson

List of Publications by Year
in descending order

67 papers	4,346 citations	109137 35 h-index	106150 65 g-index
67 all docs	67 docs citations	67 times ranked	3648 citing authors

#	Article	IF	Citations
1	Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences, 1995, 16, 33-36.	4.0	468
2	Sedation and Anesthesia Mediated by Distinct GABA_AReceptor Isoforms. Journal of Neuroscience, 2003, 23, 8608-8617.	1.7	266
3	Evidence for a Significant Role of Â3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines. Journal of Neuroscience, 2005, 25, 10682-10688.	1.7	221
4	Loss of the Major GABA_AReceptor Subtype in the Brain Is Not Lethal in Mice. Journal of Neuroscience, 2001, 21, 3409-3418.	1.7	215
5	Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 915-920.	3.3	182
6	TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for Î±2- and Î±3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 410-422.	1.3	172
7	L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for Î±5-containing GABAA receptors. Neuropharmacology, 2006, 51, 1023-1029.	2.0	162
8	Identification of a Novel, Selective GABAAÎ±5 Receptor Inverse Agonist Which Enhances Cognition. Journal of Medicinal Chemistry, 2003, 46, 2227-2240.	2.9	142
9	A Quantitative Trait Locus Influencing Anxiety in the Laboratory Rat. Genome Research, 2002, 12, 618-626.	2.4	133
10	3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues:â€‰ High-Affinity Î³-Aminobutyric Acid-A Benzodiazepine Receptor Ligands with Î±2, Î±3, and Î±5-Subtype Binding Selectivity over Î±1. Journal of Medicinal Chemistry, 2004, 47, 1807-1822.	2.9	131
11	Anxiogenic properties of an inverse agonist selective for Î± 3 subunit-containing GABAA receptors. British Journal of Pharmacology, 2005, 144, 357-366.	2.7	120
12	3-Heteroaryl-2-pyridones:Â Benzodiazepine Site Ligands with Functional Selectivity for Î±2/Î±3-Subtypes of Human GABAAReceptor-Ion Channels. Journal of Medicinal Chemistry, 2002, 45, 1887-1900.	2.9	118
13	An Orally Bioavailable, Functionally Selective Inverse Agonist at the Benzodiazepine Site of GABAA Î±5 Receptors with Cognition Enhancing Properties. Journal of Medicinal Chemistry, 2004, 47, 5829-5832.	2.9	111
14	Selective, Orally Active Î³-Aminobutyric AcidA Î±5 Receptor Inverse Agonists as Cognition Enhancers. Journal of Medicinal Chemistry, 2004, 47, 2176-2179.	2.9	106
15	Blockade of alcohol's amnestic activity in humans by an Î±5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology, 2007, 53, 810-820.	2.0	103
16	Fearfulness and sex in F2 Roman rats: males display more fear though both sexes share the same fearfulness traits. Physiology and Behavior, 2003, 78, 723-732.	1.0	84
17	A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology, 2016, 41, 1803-1812.	2.8	82
18	The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behavioural Brain Research, 1993, 57, 143-153.	1.2	81

#	Article	IF	Citations
19	One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology, 1994, 113, 570-572.	1.5	80
20	Learned fear, emotional reactivity and fear of heights: a factor analytic map from a large F2 intercross of Roman rat strains. Brain Research Bulletin, 2002, 57, 17-26.	1.4	66
21	Synthesis and Biological Evaluation of 3-Heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and Analogues as Subtype-Selective Inverse Agonists for the GABAAÎ±5 Benzodiazepine Binding Site. Journal of Medicinal Chemistry, 2004, 47, 3642-3657.	2.9	65
22	In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABA_A Receptor Î±5 Subtype-Selective Inverse Agonist. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 470-484.	1.3	63
23	Reducing Abuse Liability of GABA_A/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at Î±₁ and Î±_{2/3} Subtypes. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 4-16.	1.3	62
24	Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. Journal of Psychopharmacology, 2011, 25, 1159-1167.	2.0	61
25	Preliminary evidence of anxiolytic effects of the CRF₁ receptor antagonist R317573 in the 7.5% CO₂ proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology, 2011, 25, 1199-1206.	2.0	55
26	Predicting treatment response to antidepressant medication using early changes in emotional processing. European Neuropsychopharmacology, 2019, 29, 66-75.	0.3	52
27	Anxiolytic-like action of diazepam: which GABAA receptor subtype is involved?. Trends in Pharmacological Sciences, 2001, 22, 402.	4.0	50
28	Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. Journal of Psychopharmacology, 2007, 21, 384-391.	2.0	49
29	7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine:â€‰ A Functionally Selective Î³-Aminobutyric AcidA (GABAA) Î±2/Î±3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models. Journal of Medicinal Chemistry, 2005, 48, 7089-7092.	2.9	48
30	The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. Life Sciences, 1993, 52, 489-495.	2.0	46
31	Development of Subtype Selective GABA_AModulators. CNS Spectrums, 2005, 10, 21-27.	0.7	46
32	Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. Journal of Psychopharmacology, 2011, 25, 1256-1265.	2.0	46
33	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	13.5	44
34	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology, 2012, 22, 469-481.	0.3	40
35	Role of GABAA Î±5-containing receptors in ethanol reward: The effects of targeted gene deletion, and a selective inverse agonist. European Journal of Pharmacology, 2005, 526, 240-250.	1.7	37
36	Validating the inhalation of 7.5% CO₂ in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). Journal of Psychopharmacology, 2011, 25, 1192-1198.	2.0	36

#	Article	IF	Citations
37	Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology, 2013, 227, 331-345.	1.5	34
38	The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. Neuropsychopharmacology, 2021, 46, 1307-1314.	2.8	33
39	The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. Trials, 2017, 18, 558.	0.7	32
40	Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour. Neuropharmacology, 2004, 46, 171-178.	2.0	30
41	Effects of drugs that potentiate GABA on extinction of positively-reinforced operant behaviour. Neuroscience and Biobehavioral Reviews, 2004, 28, 229-238.	2.9	28
42	6,7-Dihydro-2-benzothiophen-4(5H)-ones:â€‰ A Novel Class of GABA-A Î±5 Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2002, 45, 1176-1179.	2.9	27
43	Genetic Mapping of Variation in Spatial Learning in the Mouse. Journal of Neuroscience, 2003, 23, 2426-2433.	1.7	26
44	RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA Î±5-SELECTIVE COMPOUND L-655,708. Drug Metabolism and Disposition, 2006, 34, 887-893.	1.7	24
45	Contribution of GABAA receptors containing Î±3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology, 2011, 215, 311-319.	1.5	24
46	Reinforcing Effects Of Compounds Lacking Intrinsic Efficacy At Î±1 Subunit-Containing GABAA Receptor Subtypes in Midazolam- But Not Cocaine-Experienced Rhesus Monkeys. Neuropsychopharmacology, 2013, 38, 1006-1014.	2.8	21
47	The GABA-A Î²3 subunit mediates anaesthesia induced by etomidate. NeuroReport, 2004, 15, 1653-1656.	0.6	20
48	Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimerâ€™s disease. Neuroscience and Biobehavioral Reviews, 2019, 97, 87-93.	2.9	20
49	Experimental medicine in psychiatry. Journal of Psychopharmacology, 2005, 19, 565-566.	2.0	17
50	The in vivo properties of pagoclone in rat are most likely mediated by 5â€²-hydroxy pagoclone. Neuropharmacology, 2006, 50, 677-689.	2.0	17
51	Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA_A Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 145-157.	1.3	17
52	EFFECTS OF REINFORCEMENT SCHEDULE ON FACILITATION OF OPERANT EXTINCTION BY CHLORDIAZEPOXIDE. Journal of the Experimental Analysis of Behavior, 2005, 84, 327-338.	0.8	15
53	Validation of experimental medicine methods in psychiatry: The P1vital approach and experience. Biochemical Pharmacology, 2011, 81, 1435-1441.	2.0	14
54	The plasmaâ€“occupancy relationship of the novel GABA_A receptor benzodiazepine site ligand, Î±5IA, is similar in rats and primates. British Journal of Pharmacology, 2009, 157, 796-803.	2.7	12

#	Article	IF	Citations
55	Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABAA receptor subtypes. Neuropharmacology, 2010, 58, 357-364.	2.0	11
56	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. Journal of Psychopharmacology, 2013, 27, 135-145.	2.0	11
57	The proconvulsant effects of the GABAA Î±5 subtype-selective compound RY-080 may not be Î±5-mediated. European Journal of Pharmacology, 2006, 548, 77-82.	1.7	10
58	Special issue on CNS experimental medicine. Journal of Psychopharmacology, 2011, 25, 1145-1147.	2.0	10
59	Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110463.	2.5	10
60	Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia. Biomarkers in Medicine, 2014, 8, 5-8.	0.6	9
61	Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients. Journal of Psychiatric Research, 2022, 145, 302-308.	1.5	9
62	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimerâ€™s disease. World Journal of Biological Psychiatry, 2022, 23, 264-277.	1.3	8
63	Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment. Journal of Psychopharmacology, 2021, 35, 1473-1478.	2.0	8
64	Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimerâ€™s disease patients. PLoS ONE, 2022, 17, e0263769.	1.1	3
65	Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition. Current Topics in Behavioral Neurosciences, 2015, 28, 475-497.	0.8	2
66	A strategy to home-in on polygenes influencing susceptibility to anxiety. Human Psychopharmacology, 1999, 14, S3-S10.	0.7	1
67	Validation of the P1vitalÂ® Faces Set for Use as Stimuli in Tests of Facial Emotion Recognition. Frontiers in Psychiatry, 2022, 13, 663763.	1.3	0